HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Moshe Rehavi Selected Research

Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)

8/2011Platelet vesicular monoamine transporter 2 density in the disruptive behavior disorders.
7/2007Reduced platelet vesicular monoamine transporter density in Tourette's syndrome pediatric male patients.
10/2005Reduced platelet vesicular monoamine transporter density in smoking schizophrenia patients.
9/2005Platelet vesicular monoamine transporter density in untreated patients diagnosed with social phobia.
3/2005Decreased platelet vesicular monoamine transporter density in children and adolescents with attention deficit/hyperactivity disorder.
8/2002Increased platelet vesicular monoamine transporter density in adult schizophrenia patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Moshe Rehavi Research Topics

Disease

8Schizophrenia (Dementia Praecox)
08/2011 - 08/2002
4Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
10/2015 - 03/2005
2Neurodegenerative Diseases (Neurodegenerative Disease)
04/2014 - 02/2009
2Cognitive Dysfunction
04/2014 - 02/2009
2Anxiety Disorders (Anxiety Disorder)
06/2012 - 05/2004
2Myocardial Infarction
01/2012 - 11/2010
2Mood Disorders (Mood Disorder)
08/2011 - 11/2008
2Social Phobia
01/2006 - 09/2005
2Drug-Related Side Effects and Adverse Reactions
10/2005 - 03/2003
1Cardiovascular Diseases (Cardiovascular Disease)
01/2012
1Hemorrhage
01/2012
1Autistic Disorder (Autism)
02/2011
1Mental Disorders (Mental Disorder)
02/2011
1Movement Disorders (Movement Disorder)
07/2007
1Tourette Syndrome (Tourette's Syndrome)
07/2007
1Infections
10/2003
1Major Depressive Disorder (Major Depressive Disorders)
11/2002

Drug/Important Bio-Agent (IBA)

6Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA
08/2011 - 08/2002
5dihydrotetrabenazineIBA
07/2007 - 08/2002
4Serotonin (5 Hydroxytryptamine)IBA
11/2010 - 01/2006
3Dopamine (Intropin)FDA LinkGeneric
10/2015 - 10/2003
3Proteins (Proteins, Gene)FDA Link
04/2015 - 05/2004
3Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA
06/2012 - 01/2006
3Pharmaceutical PreparationsIBA
10/2005 - 08/2002
2Methylphenidate (Ritalin)FDA LinkGeneric
10/2015 - 04/2015
2Brain-Derived Neurotrophic Factor (BDNF)IBA
04/2015 - 11/2008
2Messenger RNA (mRNA)IBA
04/2015 - 11/2008
2rasagiline (Azilect)FDA Link
04/2014 - 02/2009
2amsonic acid (DAS)IBA
08/2011 - 03/2005
2Antidepressive Agents (Antidepressants)IBA
11/2008 - 05/2004
2Amphetamine (Amfetamine)FDA LinkGeneric
11/2008 - 10/2003
2Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA
12/2006 - 08/2006
2Antipsychotic Agents (Antipsychotics)IBA
08/2006 - 10/2003
1Cocaine (Cocaine HCl)IBA
10/2015
1Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA
04/2015
1Thiamine (Aneurin)FDA Link
04/2014
1Biological ProductsIBA
06/2012
1Anti-Anxiety Agents (Anxiolytics)IBA
06/2012
14,4'-dibenzamido-2,2'-stilbenedisulfonic acidIBA
08/2011
1Paroxetine (Paxil)FDA LinkGeneric
02/2011
1Clozapine (Clozaril)FDA LinkGeneric
11/2008
1Nerve Growth Factors (Neurotrophins)IBA
11/2008
1Cholinergic Agents (Cholinergics)IBA
11/2008
1Muscarinic M1 ReceptorIBA
11/2008
1Haloperidol (Haldol)FDA LinkGeneric
11/2008
1Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA
11/2008
1Therapeutic UsesIBA
08/2006
1CytokinesIBA
10/2003
1Poly I-CIBA
10/2003
1EnzymesIBA
03/2003
1LigandsIBA
11/2002

Therapy/Procedure

2Drug Therapy (Chemotherapy)
04/2015 - 11/2008